After pooling, the change in monthly acute migraine-specific medication days from baseline to endpoint was significantly greater for CGRP mAbs compared to placebo (WMD = − 1.28, 95% CI = [− 1.66, − 0.90], I2 = 77%, p < 0.00001). Here, CALCA is linked to migraine disorder.